Bio-Techne Co. (NASDAQ:TECH) has seen various financial updates over the past five years. The company's stock has performed better than its underlying earnings growth and an average recommendation of 'Moderate Buy' from brokerage firms. Q3 and Q4 earnings from 2024 saw mixed results, with Q4 profits meeting expectations but a slight miss on revenue. The company's Corporate Sustainability report for 2024 has been released, emphasizing its commitment to sustainable business practices. Significant transactions include Hsbc Holdings, Virtu Financial, and American Century Companies holding substantial stock positions, and William Blair Investment Management and SVB Wealth selling off shares. The company declared a dividend and reduced its EPS estimates for FY2026 due to multiple headwinds. They announced strategic investments in Spear Bio and Wilson Wolf. Partnerships announced include expansions with Nikon Instruments Inc., Thermos Fisher Scientific, and Cell Signaling Technology. Bio-Techne's acquisition of Lunaphore expands its offerings in the spatial biology field, and its recent patent infringement lawsuit against Molecular Instruments displays its fight to protect its intellectual property.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Sun, 22 Sep 2024 08:42:25 GMT - Rating 4 - Innovation 7 - Information 8 - Rumor -4
